Cover Image
市場調查報告書

乳癌:開發中產品分析

Breast Cancer - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 229715
出版日期 內容資訊 英文 3011 Pages
訂單完成後即時交付
價格
Back to Top
乳癌:開發中產品分析 Breast Cancer - Pipeline Review, H1 2016
出版日期: 2016年06月30日 內容資訊: 英文 3011 Pages
簡介

乳癌是由乳腺細胞發病的一種癌症。一般是由乳管內壁或小葉開始。乳癌的危險因子有年齡、初經來得過早、停經太晚、過胖、荷爾蒙補充療法、口服避孕藥的使用、酒精攝取等。症狀有乳房疙瘩、乳房的大小和形狀的變化、乳房的分泌物等。治療法包含了放射線、腫瘤切除手術、乳房切除術、化療,荷爾蒙療法等。

本報告提供乳癌的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

乳癌概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 未確認階段的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停的計劃

中止開發的產品

產品開發的里程碑

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7666IDB

Summary

Global Markets Direct's, 'Breast Cancer - Pipeline Review, H1 2016', provides an overview of the Breast Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Breast Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Breast Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Breast Cancer
  • The report reviews pipeline therapeutics for Breast Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Breast Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Breast Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Breast Cancer

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Breast Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Breast Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Breast Cancer Overview
  • Therapeutics Development
  • Breast Cancer - Therapeutics under Development by Companies
  • Breast Cancer - Therapeutics under Investigation by Universities/Institutes
  • Breast Cancer - Pipeline Products Glance
  • Breast Cancer - Products under Development by Companies
  • Breast Cancer - Products under Investigation by Universities/Institutes
  • Breast Cancer - Companies Involved in Therapeutics Development
  • Breast Cancer - Therapeutics Assessment
  • Drug Profiles
  • Breast Cancer - Dormant Projects
  • Breast Cancer - Discontinued Products
  • Breast Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Breast Cancer, H1 2016
  • Number of Products under Development for Breast Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Development by Companies, H1 2016 (Contd..8)
  • Number of Products under Development by Companies, H1 2016 (Contd..9)
  • Number of Products under Development by Companies, H1 2016 (Contd..10)
  • Number of Products under Development by Companies, H1 2016 (Contd..11)
  • Number of Products under Development by Companies, H1 2016 (Contd..12)
  • Number of Products under Development by Companies, H1 2016 (Contd..13)
  • Number of Products under Development by Companies, H1 2016 (Contd..14)
  • Number of Products under Development by Companies, H1 2016 (Contd..15)
  • Number of Products under Development by Companies, H1 2016 (Contd..16)
  • Number of Products under Development by Companies, H1 2016 (Contd..17)
  • Number of Products under Development by Companies, H1 2016 (Contd..18)
  • Number of Products under Development by Companies, H1 2016 (Contd..19)
  • Number of Products under Development by Companies, H1 2016 (Contd..20)
  • Number of Products under Development by Companies, H1 2016 (Contd..21)
  • Number of Products under Development by Companies, H1 2016 (Contd..22)
  • Number of Products under Development by Companies, H1 2016 (Contd..23)
  • Number of Products under Development by Companies, H1 2016 (Contd..24)
  • Number of Products under Development by Companies, H1 2016 (Contd..25)
  • Number of Products under Development by Companies, H1 2016 (Contd..26)
  • Number of Products under Development by Companies, H1 2016 (Contd..27)
  • Number of Products under Development by Companies, H1 2016 (Contd..28)
  • Number of Products under Development by Companies, H1 2016 (Contd..29)
  • Number of Products under Development by Companies, H1 2016 (Contd..30)
  • Number of Products under Development by Companies, H1 2016 (Contd..31)
  • Number of Products under Development by Companies, H1 2016 (Contd..32)
  • Number of Products under Development by Companies, H1 2016 (Contd..33)
  • Number of Products under Development by Companies, H1 2016 (Contd..34)
  • Number of Products under Development by Companies, H1 2016 (Contd..35)
  • Number of Products under Development by Companies, H1 2016 (Contd..36)
  • Number of Products under Development by Companies, H1 2016 (Contd..37)
  • Number of Products under Development by Companies, H1 2016 (Contd..38)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..4)
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..5)
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..6)
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..7)
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..8)
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Development by Companies, H1 2016 (Contd..9)
  • Products under Development by Companies, H1 2016 (Contd..10)
  • Products under Development by Companies, H1 2016 (Contd..11)
  • Products under Development by Companies, H1 2016 (Contd..12)
  • Products under Development by Companies, H1 2016 (Contd..13)
  • Products under Development by Companies, H1 2016 (Contd..14)
  • Products under Development by Companies, H1 2016 (Contd..15)
  • Products under Development by Companies, H1 2016 (Contd..16)
  • Products under Development by Companies, H1 2016 (Contd..17)
  • Products under Development by Companies, H1 2016 (Contd..18)
  • Products under Development by Companies, H1 2016 (Contd..19)
  • Products under Development by Companies, H1 2016 (Contd..20)
  • Products under Development by Companies, H1 2016 (Contd..21)
  • Products under Development by Companies, H1 2016 (Contd..22)
  • Products under Development by Companies, H1 2016 (Contd..23)
  • Products under Development by Companies, H1 2016 (Contd..24)
  • Products under Development by Companies, H1 2016 (Contd..25)
  • Products under Development by Companies, H1 2016 (Contd..26)
  • Products under Development by Companies, H1 2016 (Contd..27)
  • Products under Development by Companies, H1 2016 (Contd..28)
  • Products under Development by Companies, H1 2016 (Contd..29)
  • Products under Development by Companies, H1 2016 (Contd..30)
  • Products under Development by Companies, H1 2016 (Contd..31)
  • Products under Development by Companies, H1 2016 (Contd..32)
  • Products under Development by Companies, H1 2016 (Contd..33)
  • Products under Development by Companies, H1 2016 (Contd..34)
  • Products under Development by Companies, H1 2016 (Contd..35)
  • Products under Development by Companies, H1 2016 (Contd..36)
  • Products under Development by Companies, H1 2016 (Contd..37)
  • Products under Development by Companies, H1 2016 (Contd..38)
  • Products under Development by Companies, H1 2016 (Contd..39)
  • Products under Development by Companies, H1 2016 (Contd..40)
  • Products under Development by Companies, H1 2016 (Contd..41)
  • Products under Development by Companies, H1 2016 (Contd..42)
  • Products under Development by Companies, H1 2016 (Contd..43)
  • Products under Development by Companies, H1 2016 (Contd..44)
  • Products under Development by Companies, H1 2016 (Contd..45)
  • Products under Development by Companies, H1 2016 (Contd..46)
  • Products under Development by Companies, H1 2016 (Contd..47)
  • Products under Development by Companies, H1 2016 (Contd..48)
  • Products under Development by Companies, H1 2016 (Contd..49)
  • Products under Development by Companies, H1 2016 (Contd..50)
  • Products under Development by Companies, H1 2016 (Contd..51)
  • Products under Development by Companies, H1 2016 (Contd..52)
  • Products under Development by Companies, H1 2016 (Contd..53)
  • Products under Development by Companies, H1 2016 (Contd..54)
  • Products under Development by Companies, H1 2016 (Contd..55)
  • Products under Development by Companies, H1 2016 (Contd..56)
  • Products under Development by Companies, H1 2016 (Contd..57)
  • Products under Development by Companies, H1 2016 (Contd..58)
  • Products under Development by Companies, H1 2016 (Contd..59)
  • Products under Development by Companies, H1 2016 (Contd..60)
  • Products under Development by Companies, H1 2016 (Contd..61)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..5)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..6)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..7)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..8)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..9)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..10)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..11)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..12)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..13)
  • Breast Cancer - Pipeline by 3-V Biosciences, Inc., H1 2016
  • Breast Cancer - Pipeline by 4SC AG, H1 2016
  • Breast Cancer - Pipeline by A&G Pharmaceutical, Inc., H1 2016
  • Breast Cancer - Pipeline by AB Science SA, H1 2016
  • Breast Cancer - Pipeline by AbbVie Inc., H1 2016
  • Breast Cancer - Pipeline by AbGenomics International, Inc., H1 2016
  • Breast Cancer - Pipeline by Ability Pharmaceuticals, S.L., H1 2016
  • Breast Cancer - Pipeline by Acceleron Pharma, Inc., H1 2016
  • Breast Cancer - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016
  • Breast Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016
  • Breast Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2016
  • Breast Cancer - Pipeline by ADC Therapeutics Sarl, H1 2016
  • Breast Cancer - Pipeline by Adgero Biopharmaceuticals, Inc., H1 2016
  • Breast Cancer - Pipeline by Aduro BioTech, Inc., H1 2016
  • Breast Cancer - Pipeline by Advanced Accelerator Applications S.A., H1 2016
  • Breast Cancer - Pipeline by Advanced Cancer Therapeutics, H1 2016
  • Breast Cancer - Pipeline by Advanced Proteome Therapeutics Corporation, H1 2016
  • Breast Cancer - Pipeline by Advaxis, Inc., H1 2016
  • Breast Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016
  • Breast Cancer - Pipeline by Aegis Therapeutics, LLC, H1 2016
  • Breast Cancer - Pipeline by Aeglea BioTherapeutics, Inc., H1 2016
  • Breast Cancer - Pipeline by Aerpio Therapeutics, Inc., H1 2016
  • Breast Cancer - Pipeline by Aeterna Zentaris Inc., H1 2016
  • Breast Cancer - Pipeline by Affichem SA, H1 2016
  • Breast Cancer - Pipeline by Agenus, Inc., H1 2016
  • Breast Cancer - Pipeline by Agilvax, Inc., H1 2016
  • Breast Cancer - Pipeline by Aileron Therapeutics, Inc., H1 2016
  • Breast Cancer - Pipeline by Alchemia Limited, H1 2016
  • Breast Cancer - Pipeline by Alethia Biotherapeutics Inc., H1 2016
  • Breast Cancer - Pipeline by Almac Discovery Limited, H1 2016
  • Breast Cancer - Pipeline by Alteogen Inc., H1 2016
  • Breast Cancer - Pipeline by Amarna Therapeutics B.V., H1 2016
  • Breast Cancer - Pipeline by Ambrx, Inc., H1 2016
  • Breast Cancer - Pipeline by American Gene Technologies International Inc., H1 2016
  • Breast Cancer - Pipeline by Amgen Inc., H1 2016
  • Breast Cancer - Pipeline by Ampio Pharmaceuticals, Inc., H1 2016
  • Breast Cancer - Pipeline by Amplyx Pharmaceuticals, Inc., H1 2016
  • Breast Cancer - Pipeline by Angion Biomedica Corp., H1 2016
  • Breast Cancer - Pipeline by ANP Technologies, Inc., H1 2016
  • Breast Cancer - Pipeline by AntiCancer, Inc., H1 2016
  • Breast Cancer - Pipeline by Antigen Express, Inc., H1 2016
  • Breast Cancer - Pipeline by Antoxis Limited, H1 2016
  • Breast Cancer - Pipeline by Aphios Corporation, H1 2016
  • Breast Cancer - Pipeline by APIM Therapeutics AS, H1 2016

List of Figures

  • Number of Products under Development for Breast Cancer, H1 2016
  • Number of Products under Development for Breast Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top